60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP)
Previous Close
$1.03
52W Range
$1.01 - $18.36
50D Avg
$1.46
200D Avg
$3.82
Market Cap
$1.92M
Avg Vol (3M)
$737.14K
Beta
5.27
Div Yield
-
SXTP Company Profile
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.